Nuclear targeted delivery of macromolecules to retina and cornea

Journal of Gene Medicine

Volumn 13, Issue 3, 2011, Pages 158-170

  Binder, Christina ^a   Read, Sarah Parker ^a   Cashman, Siobhan M ^a   Kumar Singh, Rajendra ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell penetrating peptide; Drug delivery; Gene delivery; Nucleolin; Ophthalmology

Indexed keywords

BETA GALACTOSIDASE; BINDING PROTEIN; GREEN FLUORESCENT PROTEIN; LUCIFERASE; NANOPARTICLE; NUCLEOLIN; NUCLEOLIN BINDING PEPTIDE; PLASMID DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA CELL; DRUG DELIVERY SYSTEM; ENZYME BLOOD LEVEL; MACROMOLECULE; MOUSE; NERVE CELL; NONHUMAN; PHOTORECEPTOR; PIGMENT EPITHELIUM; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA CELL; TISSUE SECTION; TRANSGENE;

ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, TOPICAL; AMINO ACID SEQUENCE; ANIMALS; BETA-GALACTOSIDASE; CELL NUCLEUS; CELL-PENETRATING PEPTIDES; CORNEA; DNA; DRUG DELIVERY SYSTEMS; ELECTRORETINOGRAPHY; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HMGN2 PROTEIN; HUMANS; INTRAVITREAL INJECTIONS; LUCIFERASES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NUCLEAR LOCALIZATION SIGNALS; PEPTIDES; PHOSPHOPROTEINS; PLASMIDS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETINA; RNA-BINDING PROTEINS;

EID: 79955128744     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1548     Document Type: Article

References (38)

1. Institute NE. 2008;
2. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127: 381-389.
3. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137: 337-342.
4. Thoft SA. The Cornea. Little, Brown, and Company: Boston, MA, 1994.
5. Wilson SE, Chaurasia SS, Medeiros FW. Apoptosis in the initiation, modulation and termination of the corneal wound healing response. Exp Eye Res 2007; 85: 305-311.
6. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: the eye. Gene Ther 2006; 13: 1191-1197.
7. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res 2008; 48: 319-324.
8. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008; 13: 135-143.
9. Jackson DA, Juranek S, Lipps HJ. Designing nonviral vectors for efficient gene transfer and long-term gene expression. Mol Ther 2006; 14: 613-626.
10. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 1647-1652.
11. Fonseca S, Pereira M, Kelly S. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009; 61: 953-964.
12. Johnson LN, Cashman SM, Read SP, et al. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res 2010; 50: 686-697.
13. Read SP, Cashman SM, Kumar-Singh R. A poly (ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo. J Gene Med 2010; 12: 86-96.
14. Cashman SM, Morris DJ, Kumar-Singh R. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol Ther 2003; 8: 130-142.
15. Kilic U, Kilic E, Dietz GP, et al. The TAT protein transduction domain enhances the neuroprotective effect of glial-cell-line-derived neurotrophic factor after optic nerve transection. Neurodegener Dis 2004; 1: 44-49.
16. Cashman SM, Sadowski SL, Morris DJ, et al. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol Ther 2002; 6: 813-823.
17. Said Hassane F, Saleh AF, Abes R, et al. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci 2010; 67: 715-726.
18. Lam AP, Dean DA. Progress and prospects: nuclear import of nonviral vectors. Gene Ther 2010; 17: 439-447.
19. Ziady AG, Gedeon CR, Miller T, et al. Transfection of airway epithelium by stable PEGylated poly L-lysine DNA nanoparticles in vivo. Mol Ther 2003; 8: 936-947.
20. Ginisty H, Sicard H, Roger B, et al. Structure and functions of nucleolin. J Cell Sci 1999; 112: 761-772.
21. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J 1999; 13: 1911-1922.
22. Deng JS, Ballou B, Hofmeister JK. Internalization of anti-nucleolin antibody into viable HEp-2 cells. Mol Biol Rep 1996; 23: 191-195.
23. Hovanessian AG, Puvion-Dutilleul F, Nisole S, et al. The cell-surface-expressed nucleolin is associated with the actin cytoskeleton. Exp Cell Res 2000; 261: 312-328.
24. Chen X, Kube DM, Cooper MJ, Davis PB. Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA. Mol Ther 2008; 16: 333-342.
25. Christian S, Pilch J, Akerman ME, et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003; 163: 871-878.
26. Hollander BA, Liang MY, Besharse JC. Linkage of a nucleolin-related protein and casein kinase II with the detergent-stable photoreceptor cytoskeleton. Cell Motil Cytoskeleton 1999; 43: 114-127.
27. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
28. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2007; 2: 1236-1247.
29. Duker YA. Ophthalmology. Mosby: China, 2008.
30. Takeshita H, Nakajima T, Mogi K, et al. Rapid quantification of DNase I activity in one-microliter serum samples. Clin Chem 2004; 50: 446-448.
31. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-4183.
32. Sawant R, Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol Biosyst 2010; 6: 628-640.
33. Chen X, Shank S, Davis PB, et al. Nucleolin-mediated cellular trafficking of DNA nanoparticle is lipid raft and microtubule dependent and can be modulated by glucocorticoid. Mol Ther 2011; 19: 93-102.
34. Johnson LN, Cashman SM, Kumar-Singh R. Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea. Mol Ther 2008; 16: 107-114.
35. Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem 2010; 50: 103-121.
36. Rudolph C, Plank C, Lausier J, et al. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 2003; 278: 11411-11418.
37. Kachi S, Oshima Y, Esumi N, et al. Nonviral ocular gene transfer. Gene Ther 2005; 12: 843-851.
38. Bejjani RA, BenEzra D, Cohen H, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005; 11: 124-132.